APA (7th ed.) Citation

Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018). Talimogene laherparepvec: First in class oncolytic virotherapy. Human vaccines & immunotherapeutics, 14(4), 839-846. https://doi.org/10.1080/21645515.2017.1412896

Chicago Style (17th ed.) Citation

Conry, Robert M., Brian Westbrook, Svetlana McKee, and Timothy Graham Norwood. "Talimogene Laherparepvec: First in Class Oncolytic Virotherapy." Human Vaccines & Immunotherapeutics 14, no. 4 (2018): 839-846. https://doi.org/10.1080/21645515.2017.1412896.

MLA (9th ed.) Citation

Conry, Robert M., et al. "Talimogene Laherparepvec: First in Class Oncolytic Virotherapy." Human Vaccines & Immunotherapeutics, vol. 14, no. 4, 2018, pp. 839-846, https://doi.org/10.1080/21645515.2017.1412896.